The latest price target for Enlivex Therapeutics (NASDAQ:ENLV) was reported by D. Boral Capital on February 7, 2025. The analyst firm set a price target for $13.00 expecting ENLV to rise to within 12 months (a possible 1198.70% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Enlivex Therapeutics (NASDAQ:ENLV) was provided by D. Boral Capital, and Enlivex Therapeutics maintained their buy rating.

There is no last upgrade for Enlivex Therapeutics

There is no last downgrade for Enlivex Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enlivex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enlivex Therapeutics was filed on February 7, 2025 so you should expect the next rating to be made available sometime around February 7, 2026.

While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a maintained with a price target of $13.00 to $13.00. The current price Enlivex Therapeutics (ENLV) is trading at is $1.00, which is out of the analyst’s predicted range.